Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bl Pharmtech Corp (065170:KRX), powered by AI.
Bl Pharmtech Corp is currently trading at ₩1,825. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bl Pharmtech Corp on Alpha Lenz.
Bl Pharmtech Corp's P/E ratio is -3.0.
“Bl Pharmtech Corp trades at a P/E of -3.0 (undervalued) with modest ROE of -104.4%.”
Ask for details →Bl Pharmtech Corp is a leading entity in the pharmaceutical and biotechnology sector, specializing in the research, development, and manufacturing of medical products and solutions. The company's primary function revolves around the innovation and distribution of pharmaceutical products aimed at treating various health conditions. Bl Pharmtech Corp's impact spans across several critical areas within the healthcare industry, including drug discovery, formulation, and clinical studies, playing a vital role in the development of new therapeutic methodologies. Noteworthy features of Bl Pharmtech Corp include its commitment to advancing biotechnology research, which aids in enhancing the efficacy and safety of medical treatments. The company serves a broad range of markets, including hospitals, clinics, and research institutions, thus holding a significant position within the global supply chain for pharmaceuticals. With its focus on producing high-quality, effective healthcare products, Bl Pharmtech Corp contributes to the improvement of public health outcomes and fosters advancement in medical technology. It stands as a pivotal player in its industry, continually adapting to the evolving needs of healthcare practices and innovations.
“Bl Pharmtech Corp trades at a P/E of -3.0 (undervalued) with modest ROE of -104.4%.”
Ask for details →Bl Pharmtech Corp (ticker: 065170) is a company listed on KRX in the Consumer Defensive sector (Food Distribution). It has approximately 12 employees. Market cap is $50.9B.
The current price is ₩1,825 with a P/E ratio of -3.04x and P/B of 6.45x.
ROE is -104.40% and operating margin is 0.36%. Annual revenue is $6.5B.